{"id":14960,"date":"2019-01-08T00:00:00","date_gmt":"2019-01-08T00:00:00","guid":{"rendered":"http:\/\/medgoo.com\/index.php\/2019\/01\/08\/cervical-cancer-screening-rates-unacceptably-low\/"},"modified":"2019-01-09T16:57:17","modified_gmt":"2019-01-09T16:57:17","slug":"cervical-cancer-screening-rates-unacceptably-low","status":"publish","type":"post","link":"https:\/\/medgoo.com\/index.php\/2019\/01\/08\/cervical-cancer-screening-rates-unacceptably-low\/","title":{"rendered":"Cervical Cancer Screening Rates &#8216;Unacceptably Low&#8217;"},"content":{"rendered":"<h3>Just 64.6 percent of 30- to 65-year-old women up to date, but Pap-HPV cotesting has increased<\/h3>\n<p><b><\/b><\/p>\n<p><b><\/b><\/p>\n<p>TUESDAY, Jan. 8, 2019 (HealthDay News) &#8212; Less than two-thirds of eligible 30- to 65-year-old women are up to date with cervical cancer screening, and Pap completion rates have decreased over time, according to a study published online Jan. 7 in the <i>Journal of Women&#8217;s Health<\/i>.<\/p>\n<p>Kathy L. MacLaughlin, M.D., from the Mayo Clinic in Rochester, Minnesota, and colleagues used data from the Rochester Epidemiology Project (2005 through 2016) to calculate three-year (Pap) and five-year (Pap-HPV) moving prevalence rates of screening as a proportion of the eligible population.<\/p>\n<p>The researchers found that in 2016, 64.6 percent of 27,418 eligible 30- to 65-year-old women were up to date with cervical cancer screening, and 60.8 percent had undergone Pap-HPV cotest screening. For all age groups, there were significant declines in Pap completion rates over time; however, Pap-HPV cotesting significantly increased at the same time among women aged 30 to 65 years, from 10 percent in 2007 to 60.8 percent in 2016.<\/p>\n<p>&#8220;These cervical cancer [screening] rates are unacceptably low,&#8221; MacLaughlin said in a statement. &#8220;We, as clinicians, must start thinking outside the box on how best to reach these women and ensure they are receiving these effective and potentially life-saving screening tests.&#8221;<\/p>\n<p>One author serves on committees overseeing safety studies of HPV vaccines funded by Merck.<\/p>\n<p><a href=\"https:\/\/www.liebertpub.com\/doi\/10.1089\/jwh.2018.7380\" target=\"_new\">Abstract\/Full Text<\/a><\/p>\n<p><i><\/i><\/p>\n<p><i>Copyright \u00a9 2019 <a href=\"https:\/\/www.healthday.com\/\" target=\"_new\">HealthDay<\/a>. All rights reserved.<\/i><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Just 64.6 percent of 30- to 65-year-old women up to date, but Pap-HPV cotesting has increased<\/p>\n","protected":false},"author":6,"featured_media":14993,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[11],"class_list":["post-14960","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news"],"_links":{"self":[{"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/posts\/14960","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/comments?post=14960"}],"version-history":[{"count":0,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/posts\/14960\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/media\/14993"}],"wp:attachment":[{"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/media?parent=14960"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/categories?post=14960"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/tags?post=14960"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}